Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Sawai Makes Downward Revision in Full-Year Sales Forecast Despite Increases in Sales, Profits in 1st Half
November 12, 2012
- Alliance with Choseido to Increase Nihon Chouzai’s Generic Lineup to 470: President Mitsuhara
November 12, 2012
- Tsumura Aims at Sales of 123 Billion Yen in FY 2015, to Expand Kampo Market: New Mid-Term Management Plan
November 12, 2012
- Sawai Sells off All Shares of Kyorin HD Following End of Talks for Business Integration
November 12, 2012
- Kaken Aims for Approval of Japan’s 1st Topical Onychomycosis Treatment Efinaconazole Next Year
November 12, 2012
- Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
- Sales Increase 3.4% as Generics Make Large Gains: Kyorin HD
November 9, 2012
- Novartis Files for Approval for LABA, LAMA Combination Treatment for COPD in Japan
November 9, 2012
- 1st-Half Settlements of Top 4 Wholesalers Suggest Recovery in Operating Profit Rates in Core Drug Business
November 9, 2012
- US FDA Approves Pfizer’s Novel RA Treatment Tofacitinib
November 9, 2012
- Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
- Sales Down by 7.8% due to Slump of Long-Listed Drugs, Transfer of Marketing Rights for Cabaser: Kissei
November 8, 2012
- Nippon Shinyaku Confident about Achieving Target in Mid-Term Management Plan Backed by Steady Growth of New Products
November 8, 2012
- Ono: New Products Grow in 1st Half, Glactiv to Become Top-Selling Product
November 8, 2012
- Alfresa HD “Reached Some Degree of Agreement with Customers” Despite Non-Agreement Rate of Over 60% in 1st Half: President Ishiguro
November 8, 2012
- Kyorin Drops Development of DPP-4 Inhibitor as It Fails to Find Partner
November 8, 2012
- Otsuka Forms JV with Turkey’s No. 1 Drug Maker, Set to Launch Samsca in 2013
November 7, 2012
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…